Company intelligence / Profile preview

Argos Therapeutics

Durham, North Carolina, United Statesargostherapeutics.com ↗

Ownership: Private
Employees: ~120
Development stage: Phase 3

Overview

The company's lead product rocapuldencel-T for metastatic renal cell carcinoma failed in Phase 3 clinical trials when an independent data monitoring committee determined it was unlikely to meet endpoints. The company also had AGS-004 for HIV which failed in Phase 2 studies in 2015.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Personalized immunotherapyRNA-loaded dendritic cell-based immunotherapyMonoclonal antibodies
Industry: Biotech

Drug pipeline

4 assets

AGS-003

Phase 3

Indications: Metastatic renal cell carcinoma

3 more assets in the full pipeline.

Request access →

Partnerships

Novo Nordisk

Beyond the preview

Go deeper on Argos Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Argos Therapeutics.

Explore the full profile